Piper Sandler analyst Matt O’Brien raised the firm’s price target on Globus Medical (GMED) to $90 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results with sales and adjusted EPS landing above expectations. Management raised full year guidance on the top- and bottom-lines by more than the beat instilling confidence in the remainder of the year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical upgraded to Buy from Neutral at BofA
- Cautious Optimism: Hold Rating for Globus Medical Amid Strong Performance and Revenue Concerns
- Globus Medical upgraded to Buy from Hold at Truist
- Globus Medical’s Strong Q3 2025 Performance and Growth
- Closing Bell Movers: Expedia up 15%, Affirm up 12% on earnings beats